[
  {
    "ts": null,
    "headline": "Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally",
    "summary": "Incyte (INCY) has been quietly outperforming the broader biotech space this year, with the stock up about 46% over the past year and more than 40% year to date, drawing fresh attention. See our latest analysis for Incyte. That move has been driven largely by renewed confidence in Incyte’s pipeline and steady revenue growth, with a robust year to date share price return helping to lift its one year total shareholder return and signal building momentum rather than a one off spike. If this kind...",
    "url": "https://finnhub.io/api/news?id=c264111412f0ddda5e9ba0b8e14c3fa0564f8e40d72387fe2760772cf9d0e42a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766095976,
      "headline": "Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally",
      "id": 137831985,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte (INCY) has been quietly outperforming the broader biotech space this year, with the stock up about 46% over the past year and more than 40% year to date, drawing fresh attention. See our latest analysis for Incyte. That move has been driven largely by renewed confidence in Incyte’s pipeline and steady revenue growth, with a robust year to date share price return helping to lift its one year total shareholder return and signal building momentum rather than a one off spike. If this kind...",
      "url": "https://finnhub.io/api/news?id=c264111412f0ddda5e9ba0b8e14c3fa0564f8e40d72387fe2760772cf9d0e42a"
    }
  },
  {
    "ts": null,
    "headline": "EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi",
    "summary": "INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.",
    "url": "https://finnhub.io/api/news?id=14729b3e881b917868092012c044e454762c72766ddab54051b45f12e06c4654",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766068200,
      "headline": "EC Approves Label Expansion of INCY's Lymphoma Drug Minjuvi",
      "id": 137825736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "INCY wins EC approval expanding Minjuvi's label, adding a new indication for relapsed or refractory follicular lymphoma after prior therapy.",
      "url": "https://finnhub.io/api/news?id=14729b3e881b917868092012c044e454762c72766ddab54051b45f12e06c4654"
    }
  },
  {
    "ts": null,
    "headline": "Incyte to Present at Upcoming Investor Conference",
    "summary": "WILMINGTON, Del., December 18, 2025--Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST).",
    "url": "https://finnhub.io/api/news?id=aee74b0fbf8e4bd4a19f7898d7425a75a6b72e2bf64317528ad769f676f072d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766062800,
      "headline": "Incyte to Present at Upcoming Investor Conference",
      "id": 137821517,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., December 18, 2025--Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST).",
      "url": "https://finnhub.io/api/news?id=aee74b0fbf8e4bd4a19f7898d7425a75a6b72e2bf64317528ad769f676f072d1"
    }
  },
  {
    "ts": null,
    "headline": "Best Defensive Stocks To Balance Tech Sector Volatility",
    "summary": "The best defensive stocks to balance risk and return combine durable cash flows, essential services, and key growth metrics. Click here to see the top 4 stocks.",
    "url": "https://finnhub.io/api/news?id=01f439f2bb0c9fe2cc0c30dcf52b790270ee9974b2cdc8ff1886a4bf66b89ca3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766046600,
      "headline": "Best Defensive Stocks To Balance Tech Sector Volatility",
      "id": 137820825,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190656202/image_2190656202.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "The best defensive stocks to balance risk and return combine durable cash flows, essential services, and key growth metrics. Click here to see the top 4 stocks.",
      "url": "https://finnhub.io/api/news?id=01f439f2bb0c9fe2cc0c30dcf52b790270ee9974b2cdc8ff1886a4bf66b89ca3"
    }
  }
]